The role of immunotherapy in small cell lung cancer.
CTLA-4
Cancer vaccines
Immune-checkpoint inhibitors
Immunotherapy
Lung cancer
PD-1
PD-L1
Journal
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
ISSN: 1699-3055
Titre abrégé: Clin Transl Oncol
Pays: Italy
ID NLM: 101247119
Informations de publication
Date de publication:
Aug 2019
Aug 2019
Historique:
received:
01
08
2018
accepted:
07
12
2018
pubmed:
15
1
2019
medline:
21
12
2019
entrez:
15
1
2019
Statut:
ppublish
Résumé
Despite decades of research, prognosis for SCLC patients remains poor, and treatment options limited. SCLC is an immunogenic tumor with high somatic mutation rates due to tobacco exposure resulting in potential neo-antigens, the presence of suppressed immune responses, and occurrence of paraneoplastic disorders. The use of T cell immune-checkpoint inhibitors (anti-PD1: nivolumab, pembrolizumab; anti-PD-L1: atezolizumab, durvalumab; anti-CTLA-4: ipilimumab, tremelimumab) have shown promising antitumor activity with the potential to prolong survival in SCLC patients. In fact, atezolizumab when combined with chemotherapy has achieved the milestone of being the first drug to improve survival in patients with newly diagnosed extensive-stage SCLC. Other immunotherapeutic approaches evaluated in clinical trials for SCLC include the use of cytokines, cancer vaccines, antiganglioside therapies, TLR9 inhibition, anti-Notch signaling, and anti-CD47. This review discusses the rationale and clinical evidence of immunotherapy in SCLC, the conflictive clinical results of novel immunotherapeutic agents and combinatorial therapies under evaluation in SCLC patients.
Identifiants
pubmed: 30637710
doi: 10.1007/s12094-018-02011-9
pii: 10.1007/s12094-018-02011-9
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
961-976Références
Lancet. 1999 Jan 9;353(9147):117-8
pubmed: 10023900
Cancer Res. 2002 Nov 1;62(21):6187-93
pubmed: 12414646
Curr Opin Drug Discov Devel. 2003 Mar;6(2):169-73
pubmed: 12669451
Eur J Cancer. 1992;28A(8-9):1387-91
pubmed: 1325176
Clin Cancer Res. 2004 Feb 1;10(3):916-23
pubmed: 14871967
Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6094-100
pubmed: 15447995
J Clin Oncol. 2005 Oct 1;23(28):6854-64
pubmed: 16192577
Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):878-87
pubmed: 16467102
Annu Rev Immunol. 2008;26:677-704
pubmed: 18173375
Clin Cancer Res. 2008 Nov 1;14(21):6770-9
pubmed: 18980970
Clin Transl Oncol. 2010 Jan;12(1):27-31
pubmed: 20080468
Curr Cancer Drug Targets. 2010 Mar;10(2):200-9
pubmed: 20201786
Expert Opin Biol Ther. 2010 Jun;10(6):983-91
pubmed: 20420527
Clin Transl Oncol. 2010 Dec;12(12):788-93
pubmed: 21156409
Cancer Immunol Immunother. 2012 Jan;61(1):9-18
pubmed: 21811785
Nature. 2011 Dec 21;480(7378):480-9
pubmed: 22193102
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6662-7
pubmed: 22451913
Chest. 2013 Jan;143(1):146-151
pubmed: 22847040
Ann Oncol. 2013 Jan;24(1):75-83
pubmed: 22858559
Nat Genet. 2012 Oct;44(10):1104-10
pubmed: 22941188
J Immunol. 1990 Feb 15;144(4):1382-6
pubmed: 2303711
Nat Rev Immunol. 2013 Apr;13(4):227-42
pubmed: 23470321
J Thorac Oncol. 2013 May;8(5):587-98
pubmed: 23546044
Ann Oncol. 2013 Oct;24 Suppl 6:vi99-105
pubmed: 23813929
Immunity. 2013 Jul 25;39(1):1-10
pubmed: 23890059
Drug Des Devel Ther. 2013 Jul 23;7:611-7
pubmed: 23901264
Cancer Chemother Pharmacol. 2014 Jul;74(1):177-83
pubmed: 24858462
J Thorac Oncol. 2015 Mar;10(3):426-30
pubmed: 25384063
J Exp Med. 1985 May 1;161(5):1135-51
pubmed: 2580935
Nucleic Acid Ther. 2015 Jun;25(3):130-40
pubmed: 25826686
Ann Oncol. 2015 Sep;26(9):1813-23
pubmed: 25922066
Drugs. 2015 May;75(8):923-7
pubmed: 25940913
Nature. 2015 Aug 6;524(7563):47-53
pubmed: 26168399
Sci Transl Med. 2015 Aug 26;7(302):302ra136
pubmed: 26311731
J Clin Oncol. 2015 Dec 1;33(34):4106-11
pubmed: 26351333
Clin Cancer Res. 2016 Feb 15;22(4):813-20
pubmed: 26880610
Transl Lung Cancer Res. 2016 Feb;5(1):26-38
pubmed: 26958491
Lancet Oncol. 2016 Jul;17(7):883-895
pubmed: 27269741
J Clin Invest. 2016 Jul 1;126(7):2610-20
pubmed: 27294525
J Thorac Oncol. 2016 Sep;11(9):1511-21
pubmed: 27296105
J Clin Oncol. 2016 Nov 1;34(31):3740-3748
pubmed: 27458307
Lancet Oncol. 2017 Jan;18(1):42-51
pubmed: 27932068
Clin Cancer Res. 2017 Jul 15;23(14):3711-3720
pubmed: 28167507
Nat Rev Cancer. 2017 Apr;17(4):209-222
pubmed: 28233802
Eur J Cancer. 2017 May;76:100-109
pubmed: 28286286
Nat Rev Clin Oncol. 2017 Sep;14(9):549-561
pubmed: 28534531
PLoS One. 2017 Jun 6;12(6):e0179170
pubmed: 28586388
J Clin Oncol. 2017 Dec 1;35(34):3823-3829
pubmed: 28813164
Mol Cancer Ther. 2017 Nov;16(11):2598-2608
pubmed: 28835386
Nat Rev Cancer. 2017 Dec;17(12):725-737
pubmed: 29077690
Lung Cancer. 2017 Oct;112:75-80
pubmed: 29191604
Front Immunol. 2017 Nov 28;8:1679
pubmed: 29234329
Transl Lung Cancer Res. 2017 Dec;6(Suppl 1):S78-S83
pubmed: 29299418
Cancer Cell. 2018 May 14;33(5):853-861.e4
pubmed: 29731394
J Thorac Oncol. 2018 Sep;13(9):1393-1399
pubmed: 29775808
N Engl J Med. 2018 Dec 6;379(23):2220-2229
pubmed: 30280641
J Thorac Oncol. 2019 May;14(5):903-913
pubmed: 30664989
J Clin Oncol. 1994 Nov;12(11):2321-6
pubmed: 7964947
J Natl Cancer Inst. 1993 Feb 17;85(4):316-20
pubmed: 8381188
J Clin Oncol. 1995 Dec;13(12):2924-30
pubmed: 8523056
Proc Natl Acad Sci U S A. 1996 May 14;93(10):4529-36
pubmed: 8643438
Lung Cancer. 1996 Sep;15(2):197-205
pubmed: 8882986
J Exp Med. 1997 Aug 29;186(5):695-704
pubmed: 9271585
Int J Cancer. 1997 Sep 26;73(1):42-9
pubmed: 9334808
Eur J Cancer. 1997 Oct;33(11):1759-66
pubmed: 9470829
Lung Cancer. 1998 Jan;19(1):25-9
pubmed: 9493137